Skip to Content
Merck
CN

Key Documents

View All Documentation

42000101

PRONOVA® UP MVG

medium viscosity sodium alginate, viscosity >200 mPa.s, 1 %(20 °C)(low), guluronate monomer units ≥60 %

Synonym(s):

High Molecular Weight TM=["PRONOVA"] UP, Alginate / Alginic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.25
UNSPSC Code:
12352201
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

form

powder

mol wt

Mw >200 kDa (approximate)

composition

guluronate monomer units, ≥60% , G/M ratio, ≥1.5

impurities

≤100 CFU/g Total viable count, ≤100 EU/g Endotoxins

pH

5.5-8.5 (20 °C, 1% in water)

viscosity

>200 mPa.s, 1 %(20 °C) (
low)

General description

PRONOVA UP MVG is a medium viscosity (greater than 200 mPas) sodium alginate where minimum 60% of the monomer units are guluronate.

Application

Examples of Pronova Alginates applications include: encapsulation of living cells and therapeutic proteins for cell therapy medications, cryoprotectant, bone putty binder for tissue engineering, 3D bioprinting, foams and cell tissue scaffolds, hydrogels, advanced drug delivery and implants, wound management, and medical devices.

Legal Information

Product of Dupont Nutrition USA, Inc.
PRONOVA is a registered trademark of International N&H USA, Inc.

Disclaimer

NOT FOR USE IN HUMANS

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Rational Design of ECMs Toward Cancer Immunotherapy

Engineered ECMs enhance immune therapy in cancer treatment by supporting cells and tissues and modulating immune response. They improve immune cell maturation, expansion, and regulation through biomaterial manipulation, acting as frameworks or carriers for enhanced tumor immunotherapy.

Global Trade Item Number

SKUGTIN
42000101-10G04065267986333
42000101-5G04065267986340